Author Interviews, Heart Disease, JAMA, Lipids / 17.04.2018
Patients With Highest LDL Levels Benefit Most From Lipid-Lowering Drugs
MedicalResearch.com Interview with:
Dr. Jennifer Robinson, MD MPH
Professor, Departments of Epidemiology & Medicine
Director, Prevention Intervention Center
Department of Epidemiology
University of Iowa
MedicalResearch.com: What is the background for this study?
Response: Compared to previous placebo-controlled statin trials, the FOURIER trial where all patients were on high or moderate intensity statin, had no reduction in cardiovascular or total mortality and the reduction in cardiovascular events was less than expected. However, other PCSK9 inhibitor trials performed in populations with higher baseline low density lipoprotein cholesterol (LDL-C) had cardiovascular risk reductions similar to that in the statin trails.
(more…)